Cargando…
The Value of the Information That Can Be Generated: Optimizing Study Design to Enable the Study of Treatments Addressing an Unmet Need for Rare Pathogens
In traditional phase 3 trials confirming safety and efficacy of new treatments relative to a comparator, a 1-sided type I error rate of 2.5% is traditionally used and typically leads to minimum sizes of 300–600 subjects per study. However, for rare pathogens, it may be necessary to work with data fr...
Autores principales: | Dane, Aaron, Rex, John H, Newell, Paul, Stallard, Nigel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290570/ https://www.ncbi.nlm.nih.gov/pubmed/35854983 http://dx.doi.org/10.1093/ofid/ofac266 |
Ejemplares similares
-
Addressing unmet needs in the treatment of COPD
por: Patalano, Francesco, et al.
Publicado: (2014) -
Quantitative proteomic studies addressing unmet clinical needs in sarcoma
por: Connolly, Elizabeth A., et al.
Publicado: (2023) -
Ionic liquids for addressing unmet needs in healthcare
por: Agatemor, Christian, et al.
Publicado: (2018) -
Novel Therapies to Address Unmet Needs in ITP
por: Mingot-Castellano, María Eva, et al.
Publicado: (2022) -
Pathogen-focused Clinical Development to Address Unmet Medical Need: Cefiderocol Targeting Carbapenem Resistance
por: Echols, Roger, et al.
Publicado: (2019)